To advance the development of the shigetec vaccine through cgmp manufacturing and release of additional cgmp lots for use in a series of phase 2 clinical trials.

Active Definitive Contract Awarded Last action

Contract number
75N93020C00048
Awardee
Awarding agency
Obligated
$11,480,630

Award facts

Contract value 45% obligated
  • $11,480,629.99 Current, with exercised options
  • $25,619,523.99 Potential, with all options
Completion date 93% complete
Current and potential, with all options
Funding agency
National Institutes of Health Department of Health and Human Services
Set-aside
No set-aside
Competition
Full and Open Competition · 4 offers Negotiated Proposal / Quote
Pricing
Cost Plus Fixed Fee
Place of performance
Austria
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action P00018 $0
Other Administrative Action P00017 $0
Exercise an Option P00016 $721,600
Funding Only Action P00015 -$2,618
Other Administrative Action P00014 $0
Other Administrative Action P00013 $0
Funding Only Action P00012 $3,964,191
Funding Only Action P00011 $198,329
Other Administrative Action P00010 $0
Other Administrative Action P00009 $0
Other Administrative Action P00008 $0
Exercise an Option P00007 $3,490,104
Other Administrative Action P00006 $0
Other Administrative Action P00005 $0
Exercise an Option P00004 $1,649,387
Other Administrative Action P00003 $0
Exercise an Option P00002 $1,244,544
Other Administrative Action P00001 $0
Original award $215,093
Show all 19

About this award

Written by GovTribe AI ·

The National Institutes of Health awarded a $25.6 million definitive contract to Eveliqure Biotechnologies GmbH on September 1, 2020, to advance the development of the Shigetec vaccine through current Good Manufacturing Practice (CGMP) manufacturing and the production of additional CGMP lots for Phase 2 clinical trials. The contract, which operates under a cost-plus-fixed-fee pricing structure with no set-aside designation, extends through March 31, 2027, and will be performed in Austria. This award supports the NIH's broader efforts to develop medical countermeasures and therapeutic interventions for public health threats.

The originating solicitation was a Special Notice/Broad Agency Announcement from the National Institute of Allergy and Infectious Diseases posted in January 2019, which sought proposals for developing medical countermeasures to address radiation and nuclear incident-related injuries. While the Shigetec vaccine contract appears to address infectious disease rather than radiological threats, it reflects the NIH's commitment to advancing vaccine development and manufacturing capabilities. The cost-plus-fixed-fee contract structure provides flexibility for the research-intensive manufacturing phase while maintaining cost controls through the fixed-fee component, allowing Eveliqure Biotechnologies to scale production for clinical evaluation of the candidate vaccine.

Quick answers

Who was awarded contract 75N93020C00048?

75N93020C00048 was awarded to Eveliqure Biotechnologies GMBH by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 1, 2020.

How much is contract 75N93020C00048 worth?

The government has obligated $11,480,630 on 75N93020C00048. Its potential value, with all options, is $25,619,524.

Which agency awarded contract 75N93020C00048?

National Institute of Allergy and Infectious Diseases (National Institutes of Health) awarded 75N93020C00048, with funding from National Institutes of Health (Department of Health and Human Services).

Was contract 75N93020C00048 competed?

The extent of competition for 75N93020C00048 was full and open competition. The government received 4 offers.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login